The Bull Case For Ionis Pharmaceuticals (IONS) Could Change Following Upgraded 2025 Revenue Guidance and Product Momentum

• Ionis Pharmaceuticals reported third-quarter 2025 results, revealing US$157 million in revenue and a net loss of US$129 million, both showing improvement from the prior year, and raised its full-year revenue guidance to US$875 million–US$900 million.
• This outlook was lifted by strong commercial performance of newly launched products like TRYNGOLZA and DAWNZERA, along with positive late-stage trial outcomes for pipeline drugs.
• We will now assess how the upward revision in Ionis's revenue guidance impacts the investment narrative around commercial expansion and clinical milestones.

Find companies with promising cash flow potential yet trading below their fair value.

Ionis Pharmaceuticals Investment Narrative Recap

For Ionis Pharmaceuticals, the key to the investment case rests on successful commercial scaling of its RNA-based therapies while steadily advancing multiple late-stage assets toward approval. The recent Q3 update, with raised revenue guidance and strong product launches, strengthens conviction in short-term commercial momentum but does not materially lower the risk tied to upcoming regulatory events for pipeline drugs, still the most important catalyst and risk for shareholders today.

Among recent developments, the release of positive Phase 3 data for olezarsen in severe hypertriglyceridemia stands out as directly relevant, as it supports Ionis's pipeline progress and underpins optimism around future FDA submissions, making upcoming regulatory outcomes especially significant for the near-term narrative.

By contrast, investors should also be aware of uncertainties around pricing and payer acceptance for expanded indications, especially as Ionis targets...

Read the full narrative on Ionis Pharmaceuticals (it's free!)

Ionis Pharmaceuticals is projected to reach $1.5 billion in revenue and $241.3 million in earnings by 2028. This outlook assumes a 16.7% annual revenue growth rate and an increase in earnings of $509.5 million from current earnings of -$268.2 million.

Uncover how Ionis Pharmaceuticals' forecasts yield a $77.07 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community place Ionis between US$36.19 and US$156.92 per share. With upcoming regulatory risk after newly raised revenue guidance, your own view matters more than ever.

Explore 4 other fair value estimates on Ionis Pharmaceuticals - why the stock might be worth 50% less than the current price!

Build Your Own Ionis Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Ionis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com